Xie Xiaohui

Associate Professor, Supervisor for Master’s Degree Candidates

Research Interests: Chronic Disease Management (Asthma, COPD, Lung Cancer and Diabetes); Clinical Pharmacy Education, Narrative Medicine

Tel: +86-010-82805020

Email:xxhrenee@bjmu.edu.cn

EDUCATION

Master of Science, Peking University (2006)

Bachelor of Science, Peking University (1990)

ACADEMIC APPOINTMENTS

2010 - Present    Peking University, School of Pharmaceutical Sciences, Department of Pharmacy Administration and Clinical Pharmacy

• Associate Professor , Supervisor for Master’s Degree Candidates

2002 - 2010    Peking University, School of Pharmaceutical Sciences, Department of Pharmacy Administration and Clinical Pharmacy

• Lecturer

1990 – 2002   Beijing Jishuitan Hospital, Department of Pharmacy

• Junior Pharmacist (1990), Senior Pharmacist (1995) 

PROFESSIONAL AFFILIATIONS

• Member of Therapeutic Drug Monitoring Research Committee, Chinese Pharmacological Society (2012);

• Academic Member of Forbidden City International conference (2009)

• Editor Board Member of Journal of Narrative Medicine (2023)

REPRESENTATIVE PUBLICATIONS

1.Yibo Wu, Shujie Dong, Xiaohui Xie*. The Transcultural Adaptation and Validation of the Chinese Version of the Duke Anticoagulation Satisfaction Scale[J]. Frontiers in Pharmacology, 2022, 13:790293.

2.Xinyi Li, Cong Huang, Xiaohui Xie*. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis[J].Journal of Clinical Pharmacy and Therapeutics, 2021, 46(2):256-266.

3.Ziyang Wu, Suhua Chen, Xiaohui Xie*. Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta-analysis[J]. Journal of Clinical Pharmacy and Therapeutics,2021, 46(2):310-318.

4.Zhou R, Wang L, Sun T, Wu Z, Xie X*. The efficacy and safety of three types of combination therapies in patients with moderate to very severe COPD: a systematic review and meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences,2019, 28(07):502-518.

5.Liqun Wang, Ruiui Zhou, Xiaohui Xie*.Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: a systematic review and meta-analysis[J]. Journal of Asthma, 2019,56(01):69-78.

6.Jiayu Cui, Ruiui Zhou, Sheng Han, Tiansheng Wang, Liqun Wang, Xiaohui Xie*.Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis[J]. Journal of clinical pharmacy and therapeutics,2018, 43(4):556-570.

7.Wang L, Xie X*, Zhou R. Assessment of the quality of randomized controlled trials on pharmaceutical care for asthmatic patients in journals of mainland China[J]. Journal of Chinese Pharmaceutical Sciences,2017,26(03):212-221